Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Renji Hospital does not have an independent "Digestive Rehabilitation Department". Instead, it is a subspecialty of digestive organ rehabilitation jointly established by the Department of Gastroenterology and the Department of Rehabilitation Medicine. Relying on the National Key Clinical Specialty Research Center for Gastroenterology and Organ Rehabilitation, it focuses on the full-cycle rehabilitation management of chronic digestive system diseases, postoperative gastrointestinal dysfunction, and brain-gut axis disorders. It is a domestic benchmark for digestive organ rehabilitation, comparable to the Munich Digestive Rehabilitation Center in Germany.

The Department of Digestive Rehabilitation at Renji Hospital is not an independent administrative department, but rather an interdisciplinary subspecialty that deeply integrates the strengths of both gastroenterology and rehabilitation medicine. The Department of Gastroenterology, founded in 1984 by Academician Jiang Shaoji and Professor Xiao Shudong, is home to the first digestive disease research institute in China. It has consistently ranked first in the Fudan University's Best Hospital Specialty Reputation Ranking for many years, with over 700,000 outpatient visits annually, ranking first in the country. The Department of Rehabilitation Medicine, established in 1953, has over 70 years of history. In 2023, it was officially designated as the "Visceral and Critical Care Rehabilitation Research Center" by the Shanghai Jiaotong University Taiping Rehabilitation Research Institute. It sees over 36,000 outpatient visits annually, ranking among the top rehabilitation departments in Shanghai.

Core business operational efficiency:

The Department of Gastroenterology has 166 inpatient beds and a 4,600-square-meter clinical endoscopy center, with over 700,000 outpatient visits and over 260,000 endoscopic procedures annually. The Department of Rehabilitation Medicine closely collaborates with clinical departments, providing early bedside rehabilitation and comprehensive rehabilitation treatment, covering critical care and organ rehabilitation, as well as perioperative respiratory function rehabilitation. The two departments work together through cross-disciplinary projects such as fatty liver exercise therapy, IBD full-cycle management, and psychosomatic treatment of functional gastrointestinal disorders.

Discipline Positioning and Core Strengths:

The core advantages can be summarized as a four-dimensional integration: "National No. 1 platform for gastroenterology × Designated organ rehabilitation center × National leader in gastrointestinal motility and psychosomatic diseases × Integration of exercise prescriptions and nutritional rehabilitation medicine and engineering." The Department of Gastroenterology has developed a series of distinctive clinical treatments in areas such as psychosomatic digestive system diseases, functional gastrointestinal disorders, inflammatory bowel disease, and chronic liver disease. The Department of Rehabilitation Medicine was designated as a "Research Center for Organ and Critical Care Rehabilitation" in 2023 and currently mainly focuses on critical care rehabilitation and organ rehabilitation. The core value of the intersection of these two departments lies in extending the management of digestive system diseases from "acute phase drug treatment" to the full cycle of "functional recovery and long-term quality of life improvement."

A national key clinical specialty for organ transplantation, and a key clinical medical center in Shanghai; Shanghai Liver Transplant Quality Control Center, and Shanghai's only national organ transplant physician training base; the world's largest single-center pediatric liver transplant center, and has ranked first in China for many consecutive years in terms of annual liver transplant volume; a national-level referral center for end-stage liver disease, pediatric hereditary liver disease, and liver cancer; benchmarked against the Liver Transplant Center of King's College Hospital, London, UK.

Founded in 2004 by Professor Xia Qiang, the Department of Hepatobiliary Surgery at Renji Hospital has grown from a small ward with 7 doctors and 10 nurses into one of the world's largest liver transplant centers in over two decades. The department specializes in adult and pediatric liver transplantation, with pediatric liver transplantation being a landmark technique. It has become a comprehensive clinical medical center integrating surgery, minimally invasive procedures, targeted therapies, and other comprehensive treatments for end-stage liver disease and liver cancer. The department is currently a National Key Clinical Specialty for Organ Transplantation, a Key Clinical Medical Center of Shanghai, a Key Clinical Specialty of Shanghai, the Shanghai Organ Transplantation and Immunological Engineering Technology Research Center, the Shanghai Organ Transplantation Institute, and the Shanghai Liver Transplantation Quality Control Center. It is also Shanghai's only National Organ Transplant Physician Training Base. Professor Xia Qiang, the discipline leader, was elected as an academician of the Chinese Academy of Engineering in 2023, leading his team to create a miracle from "starting from scratch" to "world's number one".

Core business operational efficiency:

The department performed over 800 liver transplants in both 2017 and 2018, setting a world record for a single center. As of 2023, it had completed over 3,000 pediatric liver transplants, maintaining its position as the world's leading single-center center for liver transplant volume for 10 consecutive years. Currently, it performs over 400 pediatric liver transplants annually, ranking first in the world for 12 consecutive years, with a 5-year survival rate of 93.4% and a 10-year survival rate of 92.6%. The team has performed 4,000 pediatric living donor liver transplants, achieving a 10-year overall survival rate of 92%, reaching international leading standards. 80% of pediatric liver transplants are living donor transplants, and 90% of donor retrieval surgeries are performed using laparoscopic minimally invasive techniques. The discipline has led more than 120 provincial and ministerial-level projects, including National Key Research and Development Programs and Major Research Programs of the National Natural Science Foundation of China, with research funding exceeding 100 million yuan. It has published more than 270 SCI papers in internationally authoritative journals such as Cell, Gut, Gastroenterology, and J Hepatology, with the highest single-paper impact factor being 64.5.

Discipline Positioning and Core Strengths:

The core advantages can be summarized as a four-dimensional integration: "World's largest pediatric liver transplant center × Global standard setter for minimally invasive donor liver technology × International leader in pediatric living donor liver transplantation system × Replicable and scalable 'Renji Model'". The 7th International Congress of the Society for Living Donor Liver Transplantation will be held in mainland China for the first time in 2025, marking the growing international influence of China's living donor liver transplantation. The "Renji Model" has been praised by international peers as a "learnable and replicable benchmark" globally. The department spearheaded the establishment of the first professional committee for pediatric organ transplantation in China, and led the development of the first "Clinical Diagnosis and Treatment Guidelines for Pediatric Liver Transplantation in China." It has won the second prize of the National Science and Technology Progress Award, the first prize of the Ministry of Education Science and Technology Progress Award, the first prize of the Shanghai Science and Technology Progress Award, the first prize of the Huaxia Medical Science and Technology Award, and the first prize of the Shanghai Medical Science and Technology Award.

107842154498

It is a national key clinical specialty and a key discipline of the Ministry of Education; the Shanghai Institute of Digestive Diseases and the National Health Commission's Key Laboratory of Gastroenterology; the affiliated unit of the Shanghai Gastroenterology Quality Control Center; the department of gastroenterology has long been ranked first in the national Fudan University Specialty Reputation List; a national-level center for the diagnosis and treatment of early gastrointestinal cancer, Helicobacter pylori, autoimmune liver disease, and unexplained small intestinal bleeding; and benchmarked against the Mayo Clinic's Gastroenterology Center in the United States.

The Department of Gastroenterology at Renji Hospital was founded in 1984 by Professor Jiang Shaoji, one of the first academicians of the Chinese Academy of Engineering, and Professor Xiao Shudong, a lifetime professor. At the same time, the first digestive disease research institute in China—the Shanghai Institute of Digestive Diseases—was established. The department consists of a clinical component (Department of Gastroenterology, Renji Hospital) and a laboratory component (Key Laboratory of Gastroenterology, National Health Commission), making it one of the major medical, research, and teaching bases for gastroenterology in China. Academician Jiang Shaoji, as the first director of the Shanghai Institute of Digestive Diseases, laid the foundation for the development of gastroenterology in China and made indelible contributions to the eradication of schistosomiasis. Through the inheritance and accumulation of several generations of experts such as Jiang Shaoji, Xiao Shudong, Qiu Dekai, and Fang Jingyuan, the discipline has formed the core spirit of "benevolent art to help the world and cure diseases to save lives", and has written the experience of benevolence into the history of health in China and the world.

Core business operational efficiency:

The department (East, West, and South campuses) has 166 inpatient beds, a 4,600-square-meter clinical endoscopy center, and a 1,600-square-meter laboratory. In recent years, the annual outpatient volume has exceeded 700,000 visits, ranking first in the country; the annual endoscopic diagnosis and treatment exceeds 260,000 cases, making it one of the institutions with the most comprehensive endoscopic diagnosis and treatment programs in the country. The department brings together patients with complex and critical illnesses from all over the country, forming a series of distinctive clinical treatments including gastrointestinal tumors and their precancerous diseases, chronic liver diseases (autoimmune liver disease, drug-induced liver disease, fatty liver disease, and severe liver disease), Helicobacter pylori and related diseases, inflammatory bowel disease, psychosomatic diseases of the digestive system, small intestinal bleeding, and endoscopic early cancer diagnosis and treatment.

Discipline Positioning and Core Advantages:

The department is currently a National Key Discipline (Ministry of Education), a National Key Clinical Specialty, the Shanghai Clinical Medical Center for Gastroenterology, the Shanghai Clinical Quality Control Center for Gastroenterology, and a National Key Laboratory for Gastroenterology of the National Health Commission. In 2011, it was selected as a National Key Clinical Specialty, ranking first nationwide in the Ministry of Health's evaluation. In the same year, it became one of the first batch of key clinical medical centers (Gastroenterology, Class A) in Shanghai. Renji Gastroenterology has ranked first in gastroenterology in the Fudan University specialty rankings for five consecutive years. The core advantages can be summarized as a four-dimensional integration: the foundation laid by the first digestive disease research institute in China × international leadership in early warning and chemotherapeutic prevention of gastrointestinal tumors × the only Chinese treatment for Helicobacter pylori quadruple therapy included in international guidelines × thalidomide treatment for small bowel bleeding published in NEJM rewriting global standards. The department's pioneering quadruple therapy in the field of Helicobacter pylori has become the only Chinese treatment regimen included in international guidelines; its pioneering thalidomide treatment for small bowel vascular malformation bleeding is strongly recommended by the American Gastroenterological Association international guidelines; and its research on diagnostic criteria for autoimmune liver disease has been cited and promoted by international guidelines.

A national key clinical specialty, a key discipline of the Ministry of Education, and a flagship department of the national integrated traditional Chinese and Western medicine; Shanghai branch of the National Clinical Research Center for Chronic Kidney Disease, Shanghai Peritoneal Dialysis Research Center, and Asia-Pacific Clinical Academy of Peritoneal Dialysis; a benchmark center for peritoneal dialysis in China, a national-level referral center for integrated diagnosis and treatment of end-stage renal disease, lupus nephritis, IgA nephropathy, and integrated traditional Chinese and Western medicine nephrology; benchmarked against the Department of Nephrology at the Royal Free Hospital in London, UK.

The Department of Nephrology at Renji Hospital was established in the 1960s, making it one of the earliest hospitals in my country to establish a nephrology department. From 1962 to 1963, an integrated traditional Chinese and Western medicine ward was established within the internal medicine ward of Renji Hospital to treat kidney diseases and renal insufficiency using integrated traditional Chinese and Western medicine, with the main focus on "conquering the incurable disease—uremia". In 1976, the Department of Nephrology was established as an independent department. Under the leadership of successive department directors Professor Chen Meifang, Professor Zhang Qingyi, Professor Qian Jiaqi, Professor Ni Zhaohui, and Professor Gu Leyi, the department has been developed into a national key clinical specialty, a key discipline of the Ministry of Education, one of the first batch of peritoneal dialysis training centers of the Ministry of Health, the Shanghai branch of the National Clinical Research Center for Chronic Kidney Disease, the Uremia Diagnosis and Treatment Center of Shanghai Jiao Tong University, the Shanghai Peritoneal Dialysis Research Center, the Asia-Pacific Peritoneal Dialysis Clinical College, and the first home dialysis training center in China. It also has a Level III laboratory of the State Administration of Traditional Chinese Medicine—the Molecular Cell (Kidney Disease) Laboratory.

Core business operational efficiency:

The Department of Nephrology has outpatient and inpatient services at its three campuses: East Campus, West Campus, and South Campus. It has a total of 72 specialist beds, 134 hemodialysis machines, and 16 CRRT machines. It admits over 6,000 inpatients and sees over 170,000 outpatients annually. The department currently has 49 physicians, including 11 professors/chief physicians, 8 associate professors/associate chief physicians, 4 doctoral supervisors, and 5 master's supervisors. Over 67% of the physicians hold doctoral degrees.

Discipline Positioning and Core Strengths:

The department is a national key clinical specialty and a key discipline of the Ministry of Education, and was designated a national key clinical specialty in 2012. In the 2024 Fudan University ranking of Chinese hospital specialty reputation, the Nephrology department was nominated. Its core advantages can be summarized as a four-dimensional integration: "China's cradle of peritoneal dialysis talent × the first national home dialysis training center × a high ground for precision diagnosis and treatment of rare and critical kidney diseases × a national team for the integrated prevention and treatment of kidney diseases using traditional Chinese and Western medicine." Peritoneal dialysis patients account for over 50% of the department's patients, making it one of the few departments in China with more peritoneal dialysis patients than hemodialysis patients (nationally, peritoneal dialysis patients account for only 14%). Related research has won the second prize of the National Science and Technology Progress Award. For 15 consecutive years, the department has been responsible for compiling dialysis registration data in Shanghai, making it the only data from China that has been adopted by the USRDS and published globally.

A national key clinical specialty and a key discipline under the Ministry of Education's 211 Project; ranked 6th nationally in Fudan University's specialty reputation ranking for urology; the president unit of the Yangtze River Delta Urology Alliance; the only institution in Shanghai affiliated with a urology quality control center; a national center for the diagnosis and treatment of urological oncology, urinary incontinence and pelvic floor disorders, andrology, and complex kidney transplant cases; benchmarked against the Department of Urology at the Cleveland Clinic in the United States.

The history of the Department of Urology at Renji Hospital can be traced back to the 1950s, when Professors Chen Bangdian and Wang Yijing, the first generation of urologists in China, laid the foundation for the discipline. Professor Jiang Yu established an independent urology department in the late 1960s. Through the inheritance and accumulation of successive department directors such as Jiang Yu, Wu Jiajun, and Wang Yixin, the department achieved leapfrog development under the leadership of Professors Huang Yiran and Xue Wei in the 21st century. In 2022, the department took the initiative to step out of its "comfort zone" and relocate its work focus to the old campus on the west bank of the Huangpu River. This "westward expansion" and re-establishment became a new starting point for the discipline's development.

Core business operational efficiency:

The department has 238 beds and boasts the most comprehensive urology subspecialties in China, covering 10 major subspecialties including kidney tumors, prostate tumors, bladder tumors, urinary tract stones, andrology, urinary dysfunction, urological reconstruction, pediatric urology, kidney transplantation, and urological emergencies. In 2023, the department saw nearly 446,000 outpatient and emergency visits and performed 27,000 surgeries. According to statistics on key diseases treated in Shanghai, the number of kidney tumor and bladder tumor surgeries has ranked first in Shanghai for five consecutive years, while the number of prostate tumor surgeries has consistently ranked among the top two in the city. The number of surgeries performed using the da Vinci robotic system ranks first in the country. The department has partnered with Ant Group to develop an AI-powered medical intelligence system that has served 300,000 patients in the past eight months, covering 98% of common urinary system diseases.

Discipline Positioning and Core Strengths:

The department is currently a key clinical specialty of the National Health Commission, a key discipline under the Ministry of Education's 211 Project, the only affiliated unit of the Shanghai Urology Clinical Quality Control Center, and the president unit of the Yangtze River Delta Urology Alliance. It includes the Shanghai Institute of Andrology and the editorial office of the "Chinese Journal of Andrology". It consistently ranks among the top in the country in the Fudan University's ranking of Chinese hospital specialty departments and the Chinese Academy of Medical Sciences' ranking of Chinese hospital scientific and technological influence. The core advantages can be summarized as a four-dimensional integration of "profound historical foundation × most complete subspecialties × number of da Vinci robotic surgeries nationwide × AI-enabled diagnosis and treatment process": It has the most complete 10 subspecialties in China, ranks among the top in the country in terms of clinical volume, and has reached the international first-class level in key technology fields such as kidney-preserving surgery for kidney tumors and robotic minimally invasive surgery. It also achieves technological radiation and regional leadership through the Yangtze River Delta Urology Alliance.

A national key clinical specialty in medical imaging, and the affiliated unit of the Clinical Nuclear Medicine Research Institute of Shanghai Jiao Tong University School of Medicine; consistently ranked among the top ten in nuclear medicine nationwide in Fudan University's specialty reputation rankings, and ranked first in Shanghai's nuclear medicine specialty competitiveness for three consecutive years; one of the first integrated prostate cancer diagnosis and treatment centers in China to conduct 68Ga-PSMA imaging and 177Lu-PSMA radioligand therapy (RLT); benchmarked against the Nuclear Medicine Center of Heidelberg University, Germany.

The Department of Nuclear Medicine at Renji Hospital was established in 1958. It is a research-oriented clinical specialty integrating imaging diagnosis, functional testing, radionuclide therapy, in vitro analysis, and new drug research and development and production. The department was among the first in China to grant master's and doctoral degrees in imaging medicine and nuclear medicine, and it also houses a postdoctoral research station. It is affiliated with the Clinical Nuclear Medicine Research Institute of Shanghai Jiao Tong University School of Medicine, and is a licensed laboratory for radiopharmaceuticals (Class IV). It is a key discipline of the Shanghai Municipal Education Commission, a first-class discipline of Shanghai, a plateau discipline of Shanghai, and a national key clinical specialty in medical imaging. For many consecutive years, it has ranked among the top ten in the Fudan University ranking of Chinese hospital specialty reputations, and for many years, it has ranked first in the competitiveness ranking of nuclear medicine specialties among Shanghai's top-tier hospitals. The department is the incoming chairman unit of the Nuclear Medicine Branch of the Chinese Medical Association. Professor Huang Gang serves as the chairman of the Asian-Oceanian Nuclear Medicine and Biology Consortium and the president of the Nuclear Medicine Physician Branch of the Chinese Medical Doctor Association.

Core business operational efficiency:

The department is equipped with 3 PET/CT scanners (including 1 panoramic dynamic Total-body PET/CT), 1 PET/MR scanner, 2 SPECT/CT scanners, 2 bone densitometers, a cyclotron, solid-target PET/CT, and small animal PET/CT, among other world-leading equipment. It completes tens of thousands of PET/CT examinations annually and collaborates with clinical departments to conduct PET imaging using over 70 positron-emitting molecular probes, including 68Ga-PSMA, 68Ga-DOTATATE, 68Ga-FAPI, 11C-acetic acid, 11C-choline, 18F-AV45, and 18F-PI2620. The department also undertakes numerous domestic and international multicenter clinical trials. The radionuclide therapy ward is equipped with an automated drug dispensing and remote drug delivery system, and offers treatment programs such as 131I treatment for hyperthyroidism and differentiated thyroid cancer, 89Sr/223Ra treatment for bone metastases, and 125I particle implantation.

Discipline Positioning and Core Strengths:

The core advantages can be summarized as a four-dimensional integration: "One of the birthplaces of nuclear medicine in China × National Demonstration Center for Integrated PSMA Diagnosis and Treatment × Flagship Center for 177Lu-PSMA RLT × International Leadership in the Clinical Application of Whole-Body PET/CT". The department holds a leading position in the field of integrated nuclear medicine diagnosis and treatment in China. In December 2024, it officially launched its flagship center for prostate cancer radioligand therapy (RLT), establishing a patient-centered, multidisciplinary management model. In July 2025, the department spearheaded the publication of the "Chinese Expert Consensus on the Clinical Application of PSMA PET Imaging in Prostate Cancer (2025 Edition)" and launched the clinical research project "Diagnosis of Biochemical Recurrence of Prostate Cancer with Long-Axis Field PSMA PET/CT".

The Department of Allergy at Renji Hospital is a national key clinical specialty construction unit for allergy. Founded under the leadership of renowned Chinese allergists Professor Xu Yiping and Professor Guo Yinshi, it is one of the earliest established institutions for the diagnosis and treatment of allergic diseases in China. The department has a strong foundation in allergen diagnosis and specific immunotherapy, and is characterized by its standardized desensitization treatment system and fully automated allergen detection platform, enjoying a high reputation nationwide.

Historical Origins and Spiritual Inheritance:

The department was founded under the leadership of Professor Xu Yiping (one of the founders of the Allergy Branch of the Chinese Medical Association and the Shanghai Allergy Society, and former vice chairman of the 1st and 2nd sessions of the Allergy Branch of the Chinese Medical Association) and Professor Guo Yinshi (vice chairman of the 5th and 6th sessions of the Allergy Branch of the Chinese Medical Association and the first president of the Allergy Physicians Branch of the Shanghai Medical Association). Professor Guo Yinshi served as the department director for a long time, and Professor Chen Xiaoxiang has now succeeded him as department director.

Core business operational efficiency:

The department has an allergy specialist outpatient clinic, a disease-specific outpatient clinic, an expert outpatient clinic, a special needs outpatient clinic, a specialist ward, an allergen testing laboratory, a standardized immunotherapy room, and an allergy reaction laboratory. The in vitro diagnostics department has multiple internationally advanced fully automated allergen testing systems; the in vivo diagnostics department performs skin prick tests, intradermal tests, patch tests, and complex and challenging food and drug stimulation tests. In terms of treatment, a standardized allergen-specific immunotherapy center has been established (certified by the International Allergen Standardization Committee/IQAP), and distinctive prevention and treatment measures such as specific and non-specific immunotherapy, biological targeted therapy, subcutaneous/sublingual/oral desensitization therapy, and combined biological agent desensitization therapy have been carried out.

Discipline Positioning and Benchmarking:

It is a national key clinical specialty construction unit for allergies. Professor Xu Yiping's research on "Mite Allergy and Bronchial Asthma" won the second prize of the Science and Technology Progress Award from the State Education Commission. In recent years, the department has developed strong clinical advantages in allergen diagnosis and allergen immunotherapy, and has participated in the formulation of more than ten national guidelines or expert consensus on the diagnosis and treatment of allergic diseases. Professor Guo Yinshi has served as an expert reviewer for projects and achievements of the Ministry of Science and Technology, the Ministry of Education, and the National Health Commission. He presided over the completion of the Ministry of Health project "Epidemiological Research and Standardized Prevention and Control of Major Allergic Diseases in China" (2009-2013) and the National Health and Family Planning Commission's public welfare industry research project (2015-2017).

A national key clinical specialty and a key clinical medical center in Shanghai; affiliated with the Shanghai Institute of Rheumatology and the Shanghai Clinical Quality Control Center for Rheumatology and Immunology; consistently ranked among the top three in the national specialty reputation list by Fudan University; a benchmark for the diagnosis and treatment of severe systemic lupus erythematosus (SLE) in China; the only rheumatology and immunology department in China with an independent rheumatology ICU; a translational center for cell therapy of autoimmune diseases; benchmarked against the Department of Rheumatology and Immunology at Johns Hopkins Hospital in the United States.

The Department of Rheumatology at Renji Hospital was founded in 1979 by Professor Chen Shunle, one of the founders of rheumatology in my country, and is one of the earliest departments in the country to conduct research and treatment of rheumatic diseases. The department's prototype began in 1964 when Professor Huang Mingxin guided Dr. Chen Shunle to conduct clinical and mechanistic research on autoimmune rheumatic diseases. In 1979, the Clinical Immunology Research Laboratory was established at Renji Hospital. At that time, it only had one table and three people, opened a specialist outpatient clinic and set up eight beds. This was the starting point of the Department of Rheumatology at Renji Hospital. After Chen Shunle went to Australia for further studies in 1982, he established a complete set of antibody profiles for the early diagnosis of lupus and other rheumatic diseases in China, including anti-Sm, RNP, SSA, and SSB. In 1988, he was commissioned by the National Rheumatology Society to formulate the Chinese diagnostic criteria for lupus, which was adopted as the national standard at the Second National Rheumatology Academic Conference and included in the internal medicine textbooks of college medical schools. Through the inheritance and accumulation of several generations of experts such as Chen Shunle, Bao Chunde, Shen Nan, and Ye Shuang, the discipline has formed a core spirit of "daring to be the first and pursuing excellence".

Core business operational efficiency:

The department has 120 full-time beds, including 8 beds in the nation's only rheumatology ICU and 10 GCP research beds; the number of discharged patients exceeds 5,000 annually, with key diseases accounting for over 70% of the admissions. Among these, the number of patients admitted for complex and critical illnesses such as SLE and dermatomyositis ranks first in Shanghai; the number of outpatient visits reaches 300,000 annually, ranking first in the country for many years. The department undertakes more than 40 national multi-center (lead unit) and international multi-center clinical research and original IIT research projects annually, including more than 10 cutting-edge cell therapy projects.

Discipline Positioning and Core Strengths:

The department is currently a National Key Clinical Specialty, a key clinical medical center in Shanghai, the Shanghai Rheumatology and Immunology Clinical Quality Control Center, a National Drug Clinical Research Base (Rheumatology and Immunology), one of the first units to grant master's and doctoral degrees in rheumatology, and a postdoctoral research station. It also houses the Sino-Australian Personalized Immunotherapy Center and the Shanghai Rheumatology Research Institute. It consistently ranks among the top three in China's best specialty rankings according to Fudan University. Its core advantages can be summarized as a four-dimensional integration: "Earliest foundation in rheumatology in China × A high-level center for critical care (the only rheumatology ICU in China) × A leading international force in CAR-T cell therapy for autoimmune diseases × A closed-loop chain of basic research, translation, and clinical application."

It is a national key clinical specialty and the affiliated unit of the Shanghai Human Assisted Reproductive Technology Quality Control Center; ranked among the top ten reproductive medicine departments in China in the Fudan University Specialty Reputation List, and the only reproductive specialty in Shanghai to be included in the list; one of the few national-level reproductive disease treatment centers in China that can fully carry out pedigree assisted reproduction, preimplantation genetic testing, and fertility preservation for cancer patients; benchmarked against the London Bridge Fertility Centre in the UK.

The Department of Reproductive Medicine at Renji Hospital is one of the earliest medical institutions in Shanghai to conduct clinical and research work in assisted reproductive technology. Its history dates back to 1987, when it pioneered artificial insemination services in Shanghai. In 1992, the Shanghai Human Sperm Bank was established, and in 2001, the Reproductive Medicine Center was formally established. In July 2013, the North Campus was fully operational as an independent Reproductive Medicine Center, covering an area of 6,744 square meters and a building area of 17,554 square meters. Adhering to the spirit of "benevolence and skill, benefiting the world and bringing new life," and through the development of successive discipline leaders such as Zhao Xiaoming and Sun Yun, the department has become a leading platform for reproductive medicine in China.

Core business operational efficiency:

The center sees over 400,000 outpatients annually and performs nearly 10,000 IVF cycles, ranking first in Shanghai in terms of scale and achieving internationally leading pregnancy rates. The center currently has 81 clinical medical and technical personnel, including 7 full-time principal investigators (PIs) in key laboratories, 25 senior professionals, and 5 doctoral supervisors. Since its establishment in 2003, the Shanghai Human Sperm Bank has stored a total of 124,000 sperm samples and provided approximately 120,000 qualified semen samples to over 50 reproductive medicine institutions nationwide.

Discipline Positioning and Core Strengths:

For five consecutive years, the department has ranked among the top ten reproductive specialists in the Fudan University China Hospital Rankings, first in Shanghai, and among the top five in national research standardization values. It also ranks second nationally in the Internet influence ranking of reproductive specialists among hospitals. The department's academic platforms include the Shanghai Key Laboratory of Assisted Reproduction and Eugenics, the Shanghai Human Assisted Reproductive Technology Quality Control Center (affiliated with), Shanghai's only Human Assisted Reproductive Technology Training Base, the Shanghai Branch of the National Clinical Research Center for Obstetrics and Gynecology Diseases, and the Shanghai Fertility Protection and Reconstruction Center. In 2019, it became the first center in China to pass the DNV GL & RTAC international accreditation for assisted reproduction. The core advantages can be summarized as a four-dimensional integration of "leading scale × complete platform × international certification × scientific research leadership": the sub-specialties are complete (reproductive gynecology, reproductive andrology, reproductive genetics, reproductive endoscopy, and traditional Chinese medicine reproduction), and in the past five years, it has undertaken 91 projects, including national key research and development projects, with a total research funding of over 80 million yuan, and published more than 300 papers in top international journals such as NEJM, Lancet, and JAMA.